NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis → Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (From Weiss Ratings) (Ad) Free DBVT Stock Alerts $0.56 -0.01 (-2.25%) (As of 05/31/2024 08:50 PM ET) Add Compare Share Share Today's Range$0.48▼$0.6050-Day Range$0.53▼$0.7852-Week Range$0.42▼$2.26Volume1.08 million shsAverage Volume75,371 shsMarket Capitalization$108.01 millionP/E RatioN/ADividend YieldN/APrice Target$3.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get DBV Technologies alerts: Email Address DBV Technologies MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside495.2% Upside$3.33 Price TargetShort InterestHealthy0.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 7 Articles This WeekInsider TradingSelling Shares$1,425 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.61) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.36 out of 5 starsMedical Sector550th out of 924 stocksBiological Products, Except Diagnostic Industry87th out of 151 stocks 3.2 Analyst's Opinion Consensus RatingDBV Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDBV Technologies has only been the subject of 1 research reports in the past 90 days.Read more about DBV Technologies' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.27% of the outstanding shares of DBV Technologies have been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in DBV Technologies has recently decreased by 3.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DBVT. Previous Next 1.7 News and Social Media Coverage News SentimentDBV Technologies has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for DBV Technologies this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,425.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of DBV Technologies is held by insiders.Percentage Held by Institutions71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DBV Technologies' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($0.61) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about DBV Technologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About DBV Technologies Stock (NASDAQ:DBVT)DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Read More DBVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DBVT Stock News HeadlinesMay 31 at 9:51 AM | globenewswire.comDBV Technologies Announces Plan to Implement ADS Ratio ChangeMay 31 at 4:40 AM | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.comMay 30, 2024 | globenewswire.comDBV Technologies to Participate in Upcoming EAACI 2024 CongressMay 17, 2024 | marketwatch.comDBV Technologies Plans to Change ADS RatioMay 17, 2024 | msn.comDBV Technologies to implement ADS ratio changeMay 17, 2024 | globenewswire.comDBV Technologies Announces Plan to Implement ADS Ratio ChangeMay 16, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies Announces Results of its 2024 Combined General MeetingMay 16, 2024 | globenewswire.comDBV Technologies Announces Results of its 2024 Combined General MeetingMay 9, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies to Participate in Upcoming Investor ConferencesMay 9, 2024 | globenewswire.comDBV Technologies to Participate in Upcoming Investor ConferencesMay 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for DBV Technologies with Viaskin’s Market Potential and Regulatory ProspectsMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for DBV Technologies SA Amidst Strong Clinical Progress and Solid Financial FootingMay 8, 2024 | finance.yahoo.comDBV Technologies Reports Q1 2024 Financial Results Amidst Progress and ChallengesMay 8, 2024 | investorplace.comDBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies Reports First Quarter 2024 Financial Results and Business UpdateMay 7, 2024 | marketwatch.comDBV Technologies Posts Wider 1Q Loss, Reports Going Concern DoubtsMay 7, 2024 | globenewswire.comDBV Technologies Reports First Quarter 2024 Financial Results and Business UpdateApril 25, 2024 | globenewswire.comCombined General Meeting of May 16, 2024April 4, 2024 | finance.yahoo.comInformation regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024March 20, 2024 | seekingalpha.comDBVT DBV Technologies S.A.March 15, 2024 | wsj.comDBV Technologies S.A. ADRMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial OutcomesMarch 8, 2024 | finance.yahoo.comDBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration DocumentMarch 8, 2024 | globenewswire.comDBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration DocumentSee More Headlines Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/03/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DBVT CUSIPN/A CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees104Year FoundedN/APrice Target and Rating Average Stock Price Target$3.33 High Stock Price Target$5.00 Low Stock Price Target$1.00 Potential Upside/Downside+495.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,730,000.00 Net Margins-530.89% Pretax Margin-530.76% Return on Equity-56.76% Return on Assets-43.18% Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.51 Sales & Book Value Annual Sales$15.73 million Price / Sales6.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.97Miscellaneous Outstanding Shares192,870,000Free Float189,207,000Market Cap$108.01 million OptionableOptionable Beta0.73 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Daniel Tassé (Age 64)CEO & Director Comp: $1.21MDr. Pharis Mohideen (Age 59)Chief Medical Officer Comp: $725.12kMs. Virginie Simone Jeanine Verrechia Boucinha M.B.A. (Age 55)CFO & Principal Accounting Officer Dr. Kevin P. Malobisky M.S.Ph.D., R.A.C., Chief Operations OfficerMs. Michele F. RobertsonChief Legal OfficerMs. Caroline Daniere (Age 49)Chief Human Resources Officer & Chief of Staff Dr. Wence AgbotounouChief Clinical Trial Officer & Senior VPMr. Edward P. Jordan M.B.A. (Age 56)Senior Vice President of Commercial Operations North America Alan KerrSenior VP & Head of Global Regulatory AffairsMr. Pascal WotlingChief External Manufacturing & Supply Chain OfficerMore ExecutivesKey CompetitorsOmega TherapeuticsNASDAQ:OMGAaTyr PharmaNASDAQ:LIFEVigil NeuroscienceNASDAQ:VIGLbluebird bioNASDAQ:BLUESangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsPharis MohideenSold 660 sharesTotal: $897.60 ($1.36/share)Pharis MohideenSold 382 sharesTotal: $527.16 ($1.38/share)Yiheng Capital Management L.P.Bought 327,345 shares on 5/15/2024Ownership: 2.887%Adora NduBought 1,825 shares on 2/6/2024Total: $1,624.25 ($0.89/share)Timothy E MorrisBought 12,000 shares on 8/25/2023Total: $18,240.00 ($1.52/share)View All Insider TransactionsView All Institutional Transactions DBVT Stock Analysis - Frequently Asked Questions Should I buy or sell DBV Technologies stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DBVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBVT, but not buy additional shares or sell existing shares. View DBVT analyst ratings or view top-rated stocks. What is DBV Technologies' stock price target for 2024? 3 Wall Street analysts have issued 1 year price targets for DBV Technologies' shares. Their DBVT share price targets range from $1.00 to $5.00. On average, they anticipate the company's share price to reach $3.33 in the next year. This suggests a possible upside of 495.2% from the stock's current price. View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts. How have DBVT shares performed in 2024? DBV Technologies' stock was trading at $0.9528 at the beginning of the year. Since then, DBVT shares have decreased by 41.2% and is now trading at $0.56. View the best growth stocks for 2024 here. When is DBV Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our DBVT earnings forecast. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.08. The company earned $1.41 million during the quarter, compared to the consensus estimate of $3.20 million. DBV Technologies had a negative net margin of 530.89% and a negative trailing twelve-month return on equity of 56.76%. When did DBV Technologies' stock split? Shares of DBV Technologies reverse split on the morning of Monday, June 3rd 2024. The 1-2 reverse split was announced on Monday, June 3rd 2024. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, June 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO). Who are DBV Technologies' major shareholders? DBV Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Yiheng Capital Management L.P. (2.89%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adora Ndu, Daniel B Soland, Pharis Mohideen and Timothy E Morris. View institutional ownership trends. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DBVT) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group"Trump Loophole" Beats InflationColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.